Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one,10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyl- (31868-18-5)

Mexazolam (CAS NO.31868-18-5) is also called 10-Chloro-11b-(o-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one ; BRN 1091849 ; CS 386 ; Melex ; Mexazolamum ; Mexazolamum [INN-Latin] ; UNII-S5969B6237 ; Oxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyl- . Mexazolam (CAS NO.31868-18-5) (marketed under brand name Melex and Sedoxil) is a drug which is a benzodiazepine derivative. Atorvastatin administration along with mexazolam results in a reduced elimination rate of mexazolam. Mexazolam has been trialed for anxiety and was found to be effective in alleviating anxiety at one week follow-up, however, after three weeks of therapy mexazolam had lost its therapeutic anxiolytic properties becoming no more effective than placebo, presumably due to benzodiazepine tolerance. Mexazolam is metabolised via thee CYP3A4 pathway. HMG-CoA reductase inhibitors including simvastatin, simvastatin acid, lovastatin, fluvastatin, atorvastatin and cerivastatin inhibit the metabolism of mexazolam. Pravastatin, an HMG-CoA reductase inhibitor however, does not inhibit mexazolam metabolism.